Melanoma therapy has been revolutionised. Five-year survival after metastatic cancer is a marker for highly likely continuous complete remission (CR), whereas 10-year survival after metastatic cancer is a marker for definitive cure [1,2]. In this respect, modern therapeutic options have proven to lead to a continuous CR, said Prof. Claus Garbe (Eberhard Karls University, Germany) .
In the COMBI-d and COMBI-v trials, first-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation . More than a decade ago, the diagnosis of metastatic melanoma was still a death knell: long-term survival was non-existent, only 3% of patients survived for 5 years . “The first glimmers of hope were seen i...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Cutaneous adverse events due to EGFR inhibitors Next Article
Statin use elevates risk of eczema and atopic dermatitis »